Quick Answer
CNS Pharmaceuticals, Inc. reported Cash And Cash Equivalents At Carrying Value of $7.20 million for the year ending 2025.
- CNS Pharmaceuticals, Inc. showed an increase of +11.4% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from CNS Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2019: $155.0 thousand | Q2 2019: $911.9 thousand | Q3 2019: $630.1 thousand | Q1 2020: $5.38 million | Q2 2020: $2.63 million | Q3 2020: $1.31 million | Q1 2021: $11.08 million | Q2 2021: $6.89 million | Q3 2021: $8.33 million | Q1 2022: $12.44 million | Q2 2022: $8.96 million | Q3 2022: $7.03 million | Q1 2023: $5.11 million | Q2 2023: $4.28 million | Q3 2023: $909.5 thousand | Q1 2024: $815.2 thousand | Q2 2024: $1.49 million | Q3 2024: $6.97 million | Q1 2025: $13.05 million | Q2 2025: $12.13 million | Q3 2025: $9.86 million.
- Over the full 8 years of available data (2018 to 2025), CNS Pharmaceuticals, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 2,446.9%.
- Historical annual values: Fiscal year 2025: $7.20 million | Fiscal year 2024: $6.46 million | Fiscal year 2023: $548.7 thousand | Fiscal year 2022: $10.06 million | Fiscal year 2021: $5.00 million | Fiscal year 2020: $14.04 million | Fiscal year 2019: $7.24 million | Fiscal year 2018: $282.7 thousand.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: